生物标记物在弥漫胶质瘤中的应用(4)
[14]Ohgaki H,Kleihues P.The definition of primary and secondary glioblastoma[J].Clinical Cancer Research,2013(19):764-772.
[15]Gonzalez J,de Groot J.Combination therapy for malignant glioma based on PTEN status[J].Expert Review of Anticancer Therapy,2008,8(11):1767-1779.
[16]Xiao WZ,Han DH,Wang F,et al.Relationships between PTEN gene mutations and prognosis in glioma:a meta-analysis[J].Tumor Biology,2014,35(7):6687-6693.
[17]Rodriguez FJ,Lim KS,Bowers D,et al.Pathological and molecular advances in pediatric low-grade astrocytoma[J].Annual Review of Phytopathology,2013(8):361-379.
[18]Hegi ME,Diserens AC,Gorlia T,et al.MGMT gene silencing and benefit from temozolomide in glioblastoma[J].The New England Journal of Medicine,2005,352(10):997-1003.
[19]Nakamura M,Watanabe T,Yonekawa Y,et al.Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene[J].Carcinogenesis,2001,22(10):1715-1719.
[20]Tabouret E,Nguyen AT,Dehais C.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort[J].Acta Neuropathologica,2016,132(4):625-634.
[21]茆晨雪,周宏灏,刘昭前.弥漫性胶质瘤生物标志物的发现及研究进展[J].中国临床药理学与治疗学,2016,21(1):93-98.
[22]杨燕武,毛庆.胶质瘤诊断和预后标志物的研究进展[J].中国神经肿瘤杂志,2012(1):45-50.
[23]李密馥,李鹏,黄海燕,等.肿瘤干细胞标记物在胶质瘤临床应用中的研究[J].中国免疫学杂志,,2014(7):1002-1005.
[24]李朝晖,郭志钢,李庆伟.弥漫性较低级别胶质瘤的整合性分子病理分型研究进展[J].中国肿瘤临床,2016(12):541-544.
[25]任艳明,肖安琪,杨翔,等.弥漫性脑干胶质瘤研究现状[J].华西医学,2016(04):775-779.
[26]涂艷阳,祁婧,张永生.胶质瘤中分子标记物的应用进展[J].转化医学电子杂志,2016,3(7):1-5.
[27]郭素红,卢洁,于常海.生物标记检测在神经胶质瘤诊断中的研究进展[J].吉林医药学院学报,2009,30(6):352-357.
[28]于士柱,王虔.胶质瘤生物学标志的研究进展及其应用前景[J].中华病理学杂志,2009,38(3):145-147.
[29]王子威,贾秀志, 任欢.恶性胶质瘤生物学标志物的研究进展[J].国际免疫学杂志,2013,36(3):170-173.
[30]胡新华,刘宏毅.分子标志物应用于恶性胶质瘤诊治的研究进展[J].中国微侵袭神经外科杂志,2011,16(9):426-428.
编辑/王海静, 百拇医药(马晓菁)
[15]Gonzalez J,de Groot J.Combination therapy for malignant glioma based on PTEN status[J].Expert Review of Anticancer Therapy,2008,8(11):1767-1779.
[16]Xiao WZ,Han DH,Wang F,et al.Relationships between PTEN gene mutations and prognosis in glioma:a meta-analysis[J].Tumor Biology,2014,35(7):6687-6693.
[17]Rodriguez FJ,Lim KS,Bowers D,et al.Pathological and molecular advances in pediatric low-grade astrocytoma[J].Annual Review of Phytopathology,2013(8):361-379.
[18]Hegi ME,Diserens AC,Gorlia T,et al.MGMT gene silencing and benefit from temozolomide in glioblastoma[J].The New England Journal of Medicine,2005,352(10):997-1003.
[19]Nakamura M,Watanabe T,Yonekawa Y,et al.Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene[J].Carcinogenesis,2001,22(10):1715-1719.
[20]Tabouret E,Nguyen AT,Dehais C.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort[J].Acta Neuropathologica,2016,132(4):625-634.
[21]茆晨雪,周宏灏,刘昭前.弥漫性胶质瘤生物标志物的发现及研究进展[J].中国临床药理学与治疗学,2016,21(1):93-98.
[22]杨燕武,毛庆.胶质瘤诊断和预后标志物的研究进展[J].中国神经肿瘤杂志,2012(1):45-50.
[23]李密馥,李鹏,黄海燕,等.肿瘤干细胞标记物在胶质瘤临床应用中的研究[J].中国免疫学杂志,,2014(7):1002-1005.
[24]李朝晖,郭志钢,李庆伟.弥漫性较低级别胶质瘤的整合性分子病理分型研究进展[J].中国肿瘤临床,2016(12):541-544.
[25]任艳明,肖安琪,杨翔,等.弥漫性脑干胶质瘤研究现状[J].华西医学,2016(04):775-779.
[26]涂艷阳,祁婧,张永生.胶质瘤中分子标记物的应用进展[J].转化医学电子杂志,2016,3(7):1-5.
[27]郭素红,卢洁,于常海.生物标记检测在神经胶质瘤诊断中的研究进展[J].吉林医药学院学报,2009,30(6):352-357.
[28]于士柱,王虔.胶质瘤生物学标志的研究进展及其应用前景[J].中华病理学杂志,2009,38(3):145-147.
[29]王子威,贾秀志, 任欢.恶性胶质瘤生物学标志物的研究进展[J].国际免疫学杂志,2013,36(3):170-173.
[30]胡新华,刘宏毅.分子标志物应用于恶性胶质瘤诊治的研究进展[J].中国微侵袭神经外科杂志,2011,16(9):426-428.
编辑/王海静, 百拇医药(马晓菁)